Skip to main content
ALGS
NASDAQ Life Sciences

Aligos 10-Q: $31.1M Cash Funds Operations Only Into Q1 2027, Going Concern Flagged

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$4.46
Mkt Cap
$28.163M
52W Low
$3.98
52W High
$13.689
52W Position info
12% above low
Off High info
67% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ALGS is trading near its 52-week low of $3.98 (12% above the low).

Summary

Aligos closed Q3 with $31.1 million in cash — enough to fund operations only into Q1 2027 — and flagged substantial doubt about its ability to continue as a going concern, with the key Phase 2 HBV data not expected until late Q3 2027.


Key Events · Earnings and Guidance · ALGS

  • Going Concern Warning on Thin Runway

    Cash and cash equivalents of $31.1 million at September 30, 2026 are expected to fund planned operations only into Q1 2027 — less than 12 months from the filing date — raising substantial doubt about the company's ability to continue as a going concern.

  • Q3 Loss Narrows but Comparison Misleading

    Q3 2026 net loss was $21.9 million ($2.09 per share) versus $31.5 million ($3.04) a year earlier; the nine-month loss widened to $46.4 million from $4.3 million because 2025 included a $58.97 million non-cash warrant remeasurement gain.

  • Amoytop Upfront Is the Only Real Inflow

    The May 2026 Greater China license for pevifoscorvir sodium brought a $25.0 million upfront (net of Chinese withholding tax), received in July 2026 and recognized as $27.8 million of licensing revenue in the nine months, against up to $420 million in milestones.

  • Warrant Remeasurement Is Non-Cash

    The $6.56 million nine-month gain on the 2023 common warrants cut the liability to $5.6 million from $12.2 million; this is a mark-to-market accounting entry tied to the share price, not dilution, new warrants or cash.


Analysis · ALGS · Life Sciences

The headline loss is smaller than a year ago, but that comparison is misleading: last year's nine-month figure was flattered by a $59.0 million non-cash warrant remeasurement gain that did not repeat. Liquidity is the real story. Aligos ended September with $31.1 million in cash and no short-term investments, down from $77.8 million at year-end, and management states plainly that this funds operations only into the first quarter of 2027 — less than twelve months out — raising substantial doubt about the company's ability to continue as a going concern. The only meaningful cash inflow was the $25.0 million Amoytop upfront for Greater China rights to pevifoscorvir sodium, already received in July. With the Phase 2 B-SUPREME topline not due until late Q3 2027, the company must raise capital before that readout, and any equity raise would come at a share price far below the $18.92 and $26.02 strikes on its outstanding warrants.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ALGS was trading at $4.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.2M. The 52-week trading range was $3.98 to $13.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ALGS - Latest Insights

ALGS
Nov 06, 2026, 8:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $4.51
Real-time Price: $1.17 info
Change: -$3.34 (-74%) info
Market Cap: $8.599M info
ALGS
Aug 12, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $1.17 info
Change: -$5.83 (-83%) info
Market Cap: $8.599M info
ALGS
Aug 06, 2026, 8:19 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.52
Real-time Price: $1.17 info
Change: -$3.35 (-74%) info
Market Cap: $8.599M info
ALGS
Aug 06, 2026, 8:07 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $4.52
Real-time Price: $1.17 info
Change: -$3.35 (-74%) info
Market Cap: $8.599M info
ALGS
Aug 06, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.52
Real-time Price: $1.17 info
Change: -$3.35 (-74%) info
Market Cap: $8.599M info